Compared to the CD133− cells, CD133+ cells from tissue samples of non-small cell lung cancer patients and lung cancer cell lines had higher expressions of Oct-4 and better in vitro and in vivo self-renewal capability [68]. This evidence concerns the gene PROM1 and non-small cell lung carcinoma.